These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029 [TBL] [Abstract][Full Text] [Related]
4. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2 Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771 [TBL] [Abstract][Full Text] [Related]
5. PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2 Pastore F; Bhagwat N; Pastore A; Radzisheuskaya A; Karzai A; Krishnan A; Li B; Bowman RL; Xiao W; Viny AD; Zouak A; Park YC; Cordner KB; Braunstein S; Maag JL; Grego A; Mehta J; Wang M; Lin H; Durham BH; Koche RP; Rampal RK; Helin K; Scherle P; Vaddi K; Levine RL Cancer Discov; 2020 Nov; 10(11):1742-1757. PubMed ID: 32669286 [TBL] [Abstract][Full Text] [Related]
6. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200 [TBL] [Abstract][Full Text] [Related]
7. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis. Ueda F; Tago K; Tamura H; Funakoshi-Tago M J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978 [TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975 [TBL] [Abstract][Full Text] [Related]
9. The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock. West AC; Martin BP; Andrews DA; Hogg SJ; Banerjee A; Grigoriadis G; Johnstone RW; Shortt J Oncogenesis; 2016 Apr; 5(4):e216. PubMed ID: 27043662 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Ishida S; Akiyama H; Umezawa Y; Okada K; Nogami A; Oshikawa G; Nagao T; Miura O Oncotarget; 2018 Jun; 9(42):26834-26851. PubMed ID: 29928488 [TBL] [Abstract][Full Text] [Related]
13. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Manshouri T; Estrov Z; Quintás-Cardama A; Burger J; Zhang Y; Livun A; Knez L; Harris D; Creighton CJ; Kantarjian HM; Verstovsek S Cancer Res; 2011 Jun; 71(11):3831-40. PubMed ID: 21512135 [TBL] [Abstract][Full Text] [Related]
14. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936 [TBL] [Abstract][Full Text] [Related]
15. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
16. The implication of identifying JAK2 ( V617F ) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. Olsen RJ; Dunphy CH; O'Malley DP; Rice L; Ewton AA; Chang CC J Hematop; 2008 Sep; 1(2):111-7. PubMed ID: 19669209 [TBL] [Abstract][Full Text] [Related]
17. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant]. Funakoshi-Tago M Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718 [TBL] [Abstract][Full Text] [Related]
18. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189 [TBL] [Abstract][Full Text] [Related]
20. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]